Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate

✍ Scribed by Ambrose Aboud; Aman U. Buzdar; Hwee-Yong Yap; Gabriel N. Hortobagyi; George R. Blumenschein

• Publisher: John Wiley and Sons
• Year: 1984
• Tongue: English
• Weight: 270 KB
• Volume: 26
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930260315

✦ Synopsis

Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue. Of 24 evaluable patients, one achieved a complete remission and 17 had partial responses. The overall objective response rate was 75%. The median survival from initiation of chemotherapy for the responding patients was 18 months. Four patients (17%) with stable disease had a median survival of 25 months. The addition of MTX to FAC chemotherapy did not improve the therapeutic efficacy of this combination; it did, however, increase the overall toxicity, especially the infectious complications when compared to FAC alone.